Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons

被引：10

作者：

Daniels L.B. ^{[1
]}

机构：

[1] Division of Cardiology, University of California, San Diego, La Jolla, CA, 92037-1300, MC 0986, 9350 Campus Point Drive

来源：

Current Cardiovascular Risk Reports | 2010年 / 4卷 / 2期

关键词：

Natriuretic peptides; Primary prevention; Risk assessment; Screening;

D O I：

10.1007/s12170-010-0078-8

中图分类号：

学科分类号：

摘要：

Current tools for cardiovascular disease (CVD) risk assessment in asymptomatic individuals are imperfect. Preventive measures aimed only at individuals deemed high risk by current algorithms neglect large numbers of low-risk and intermediate-risk individuals who are destined to develop CVD and who would benefit from early and aggressive treatment. Natriuretic peptides have the potential both to identify individuals at risk for future cardiovascular events and to help detect subclinical CVD. Choosing the appropriate subpopulation to target for natriuretic peptide testing will help maximize the performance and the cost effectiveness. The combined use of multiple risk markers, including biomarkers, genetic testing, and imaging or other noninvasive measures of risk, offers promise for further refining risk assessment algorithms. Recent studies have highlighted the utility of natriuretic peptides for preoperative risk stratification; however, cost effectiveness and outcomes studies are needed to affirm this and other uses of natriuretic peptides for cardiovascular risk assessment in asymptomatic individuals. © 2010 The Author(s).

引用

页码：120 / 127

页数：7

共 65 条

[31]

Mogelvang R., Goetze J.P., Pedersen S.A., Et al., Preclinical systolic and diastolic dysfunction assessed by tissue doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations, J Card Fail, 15, pp. 489-495, (2009)

[32]

Gerber I.L., Legget M.E., West T.M., Et al., Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration, Am J Cardiol, 95, pp. 898-901, (2005)

[33]

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions The SOLVD Investigators, N Engl J Med, 327, pp. 685-691, (1992)

[34]

Julius S., Nesbitt S.D., Egan B.M., Et al., Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354, pp. 1685-1697, (2006)

[35]

Nakamura M., Endo H., Nasu M., Et al., Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population, Heart, 87, pp. 131-135, (2002)

[36]

Nielsen O.W., McDonagh T.A., Robb S.D., Dargie H.J., Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population, J Am Coll Cardiol, 41, pp. 113-120, (2003)

[37]

Heidenreich P.A., Gubens M.A., Fonarow G.C., Et al., Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction, J Am Coll Cardiol, 43, pp. 1019-1026, (2004)

[38]

Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Et al., Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study, Circulation, 109, pp. 3176-3181, (2004)

[39]

Vasan R.S., Benjamin E.J., Larson M.G., Et al., Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study, Jama, 288, pp. 1252-1259, (2002)

[40]

McDonagh T.A., Robb S.D., Murdoch D.R., Et al., Biochemical detection of left-ventricular systolic dysfunction, Lancet, 351, pp. 9-13, (1998)

← 1 2 3 4 5 6 7 →